相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diagnosis and Management of Multiple Myeloma A Review
Andrew J. Cowan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
CDK9 inhibitors in multiple myeloma: a review of progress and perspectives
Jedrzej Borowczak et al.
MEDICAL ONCOLOGY (2022)
Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
Stefania Fiorcari et al.
FRONTIERS IN ONCOLOGY (2022)
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams
Darren Pan et al.
FRONTIERS IN ONCOLOGY (2022)
Exosomes in multiple myeloma: from bench to bedside
Eline Menu et al.
BLOOD (2022)
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
Jennifer Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
Sandra Weller et al.
CELL DEATH DISCOVERY (2022)
A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)
Alvaro J. Alencar et al.
BLOOD (2021)
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma
Riccardo Castelli et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
Yuanyuan Jin et al.
ANNALS OF HEMATOLOGY (2021)
Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels
Jiayan Gu et al.
CYTOKINE (2021)
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death (vol 7, 15278, 2017)
Sook-Kyoung Heo et al.
SCIENTIFIC REPORTS (2021)
Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks in vivo tumor growth
Renate Burger et al.
HAEMATOLOGICA (2021)
Targeting MCL-1 in cancer: current status and perspectives
Haolan Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells
Anne Slomp et al.
CELL DEATH & DISEASE (2021)
Targeting CDK9 for Anti-Cancer Therapeutics
Ranadip Mandal et al.
CANCERS (2021)
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
Abel Tesfaye Anshabo et al.
FRONTIERS IN ONCOLOGY (2021)
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J. Bahlis et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Omar Al-Odat et al.
FRONTIERS IN PHARMACOLOGY (2021)
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Arnold Bolomsky et al.
BLOOD ADVANCES (2021)
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Luciano J. Costa et al.
BLOOD ADVANCES (2021)
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
Mariana Villalobos-Ortiz et al.
CELL DEATH AND DIFFERENTIATION (2020)
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Esperanza M. Algarin et al.
HAEMATOLOGICA (2020)
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Justin Cidado et al.
CLINICAL CANCER RESEARCH (2020)
Hot-Spots of Mcl-1 Protein
Camille Denis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress
Roberto Ronca et al.
CANCER RESEARCH (2020)
Saga of Mcl-1: regulation from transcription to degradation
Viacheslav V. Senichkin et al.
CELL DEATH AND DIFFERENTIATION (2020)
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
Carolane Seiller et al.
CELL DEATH & DISEASE (2020)
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Roberto Ria et al.
JOURNAL OF CLINICAL MEDICINE (2020)
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B. Balachander et al.
CLINICAL CANCER RESEARCH (2020)
Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
Su-Lin Lim et al.
PLOS ONE (2020)
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
Qiuyun Luo et al.
ONCOLOGY RESEARCH (2020)
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
Monika Stetkova et al.
CELL DEATH & DISEASE (2020)
Cytokine profile in multiple myeloma
Shivali Jasrotia et al.
CYTOKINE (2020)
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor
Sean Caenepeel et al.
CANCER RESEARCH (2020)
BCL2 blockade overcomes MCL1 resistance in multiple myeloma
Ka Tat Siu et al.
LEUKEMIA (2019)
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma
Phyllis S. Y. Chong et al.
CANCER RESEARCH (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan et al.
NATURE MEDICINE (2019)
Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
Anne Slomp et al.
BLOOD ADVANCES (2019)
CDK9: A key player in cancer and other diseases
Lia Carolina Franco et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V. Shah et al.
LEUKEMIA (2018)
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Calla M. Olson et al.
NATURE CHEMICAL BIOLOGY (2018)
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Yawara Kawano et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Sean Caenepeel et al.
CANCER DISCOVERY (2018)
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
Patricia Gomez-Bougie et al.
BLOOD (2018)
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron et al.
NATURE COMMUNICATIONS (2018)
Anti-apoptotic BCL-2 family members in development
Joseph T. Opferman et al.
CELL DEATH AND DIFFERENTIATION (2018)
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale et al.
CELL DEATH AND DIFFERENTIATION (2018)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma
Vikas A. Gupta et al.
BLOOD (2017)
Developmental Regulation of Mitochondria! Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics
Kristopher A. Sarosiek et al.
CANCER CELL (2017)
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
C. Touzeau et al.
LEUKEMIA (2016)
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
R. Bajpai et al.
ONCOGENE (2016)
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
Jia-Nan Gong et al.
BLOOD (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells
Tobias S. Slordahl et al.
ONCOTARGET (2016)
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
Teru Hideshima
Therapeutics and Clinical Risk Management (2016)
Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies
Luke F. Peterson et al.
BLOOD (2015)
miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Yijun Yang et al.
CLINICAL CANCER RESEARCH (2015)
Targeting B-cell maturation antigen in multiple myeloma
Yu-Tzu Tai et al.
IMMUNOTHERAPY (2015)
Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death
Gabriel Ichim et al.
MOLECULAR CELL (2015)
Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma
Michael G. Alexandrakis et al.
PATHOLOGY & ONCOLOGY RESEARCH (2015)
Small molecule Mcl-1 inhibitors for the treatment of cancer
Johannes Belmar et al.
PHARMACOLOGY & THERAPEUTICS (2015)
The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
Jinheng Wang et al.
ONCOTARGET (2015)
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
Kim De Veirman et al.
Oncotarget (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Shaji K. Kumar et al.
BLOOD (2015)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
Jinheng Wang et al.
BLOOD (2014)
Arylazopyrazole AAP1742 Inhibits CDKs and Induces Apoptosis in Multiple Myeloma Cells via Mcl-1 Downregulation
Radek Jorda et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2014)
Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF
Jiang-hua Ding et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2Mcl-1 pathway
Ken Sadahira et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma
J. Huo et al.
LEUKEMIA (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
Apoptosis therapy: driving cancers down the road to ruin
Douglas R. Green et al.
NATURE MEDICINE (2013)
Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Nathan G. Dolloff et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Negative Regulation of the Stability and Tumor Suppressor Function of Fbw7 by the Pin1 Prolyl Isomerase
Sang-Hyun Min et al.
MOLECULAR CELL (2012)
Bone Marrow-Derived Mesenchymal Stromal Cells are Attracted by Multiple Myeloma Cell-Produced Chemokine CCL25 and Favor Myeloma Cell Growth in Vitro and In Vivo
Song Xu et al.
STEM CELLS (2012)
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
A. Kalff et al.
BLOOD CANCER JOURNAL (2012)
Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1
Yi-Kun Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
ABT-737 is highly effective against molecular subgroups of multiple myeloma
Linda Bodet et al.
BLOOD (2011)
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells
Alejo A. Morales et al.
BLOOD (2011)
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
Sally A. Hunsucker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Triona Ni Chonghaile et al.
SCIENCE (2011)
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms
Elke De Bruyne et al.
BLOOD (2010)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
Scott Ackler et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma
Lia E. Perez et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Wei-Gang Tong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Martin Schwickart et al.
NATURE (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
L. Santo et al.
ONCOGENE (2010)
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Andrew Conroy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Different forms of cell death induced by putative BCL2 inhibitors
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
N. Raje et al.
LEUKEMIA (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis
K. Podar et al.
ONCOGENE (2008)
The malignant clone and the bone-marrow environment
Klaus Podar et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57*cytotoxic T cells as predictors of outcome
Linda Mileshkin et al.
HAEMATOLOGICA (2007)
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells
M. P. Kline et al.
LEUKEMIA (2007)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
Patricia Gomez-Bougie et al.
CANCER RESEARCH (2007)
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation (Publication with Expression of Concern. See vol. 24, pg. 4346, 2018)
Manisha Bhutani et al.
CLINICAL CANCER RESEARCH (2007)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D. Chauhan et al.
ONCOGENE (2007)
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Suzanne Trudel et al.
CLINICAL CANCER RESEARCH (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Chemokines in multiple myeloma
Rohit Aggarwal et al.
EXPERIMENTAL HEMATOLOGY (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
T Strömberg et al.
BLOOD (2006)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
AM Roccaro et al.
CANCER RESEARCH (2006)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
N Raje et al.
BLOOD (2005)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
S Wuillème-Toumi et al.
LEUKEMIA (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
Immunomodulation of multiple myeloma
TM Tohnya et al.
CANCER BIOLOGY & THERAPY (2004)
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
S Le Gouill et al.
BLOOD (2004)
The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells
P Gomez-Bougie et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib
K Podar et al.
CANCER RESEARCH (2004)
Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils
SJ Gardai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Novel therapeutic approaches for multiple myeloma
T Hideshima et al.
IMMUNOLOGICAL REVIEWS (2003)
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells
M Jourdan et al.
ONCOGENE (2003)
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
G Bisping et al.
BLOOD (2003)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K Dredge et al.
BRITISH JOURNAL OF CANCER (2002)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells:: therapeutic implications
CS Mitsiades et al.
ONCOGENE (2002)
Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells -: Regulation during interleukin-6 (IL-6)-induced growth and survival
H Spets et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity
N Sato et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells
YT Tai et al.
BLOOD (2002)
5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis
DK Price et al.
THERAPEUTIC DRUG MONITORING (2002)
Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells
T Otsuki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta et al.
LEUKEMIA (2001)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
K Podar et al.
BLOOD (2001)
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells
D Chauhan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro
WC Cheung et al.
LEUKEMIA (2001)
Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule
D Puthier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1
M Jourdan et al.
CELL DEATH AND DIFFERENTIATION (2000)
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
B Dankbar et al.
BLOOD (2000)
Viewpoint on the impact of interferon in the treatment of multiple myeloma:: benefit for a small proportion of patients?
J Bladé et al.
MEDICAL ONCOLOGY (2000)
分享论文
